ARQT Projected Dividend Yield
Arcutis Biotherapeutics Inc ( NASDAQ : ARQT )Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. Co. is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. Co.'s pipeline includes ARQ-255, ARQ-252, and ARQ-234. 21 YEAR PERFORMANCE RESULTS |
ARQT Dividend History Detail ARQT Dividend News ARQT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |